Evox partnership with Takeda Pharmaceutical for rare disease
Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited. The... Read More
AstraZeneca and Silence Therapeutics co-development siRNA therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular (CV),... Read More
A case based understanding in co-development deal
In a Co-Development Agreement the intellectual property is typically licensed by the licensor to the alliance partner, and as well, the two... Read More
RIBOMIC – AJU Pharma licensing deal for RBM-007 in age-related macular degeneration
Posted on20 Mar 2020
Comments0
RBOMIC has finalized the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company. This deal is for RBM-007 licensing agreement for... Read More
AstraZeneca disinvest hypertension medicines to Atnahs Pharma
AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide... Read More
Case Study: AstraZeneca to sublicense its global rights to Movantik
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is... Read More
Beximco and Mylan’s licensing deal for biosimilar in Bangladesh
Posted on28 Feb 2020
TagsBeximco Pharmaceuticals, licensing deal in pharma, Mylan, mylan licensing deal, Ogivri, trastuzumab
Comments0
Under the terms of the agreement, Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to... Read More
Insight on Hikma and Glenmark’s Exclusive Licensing Agreement for Commercialising Ryaltris Nasal Spray in the US
Posted on28 Feb 2020
Tagsdrug licensing, Glemark outlicensing, Glenmark, global pharma licensing deal, Hikma, inlicensing in pharma, Ryaltris
Comments0
Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company signed of an exclusive... Read More
Stada acquired 15 OTC brands of GSK
Stada Arzneimittel AG has acquired 15 consumer healthcare products, including those specializing in vitamins, cold treatments, and sore throat medication, from GlaxoSmithKline... Read More
Case Study : Rx-to-OTC switch of Voltaren arthritis pain
In this article we will be understanding about the Rx-to-OTC switch of Voltaren arthritis pain. It is one of the drug which... Read More